Slate Medicines Raises $130M in Series A Funding

The biotech launches with financing to take its licensed anti-PACAP antibody into clinical trials.

Round size
$130M
Stage
Series A
Headquarters
United States
Announced
Feb 24, 2026

A different target for migraine prevention

Slate’s lead program, SLTE-1009, targets PACAP, a pathway distinct from the CGRP target used by existing migraine medicines. Licensed from DartsBio Pharmaceuticals, the antibody was engineered for a longer half-life and subcutaneous administration.

Preparing for clinical development

RA Capital Management, Forbion and Foresite Capital co-led the $130 million Series A, joined by another undisclosed biotech investor. At launch, Slate planned to begin Phase 1 testing in mid-2026 and was also advancing an undisclosed pipeline of headache treatments.

Sources

  1. Slate Medicines: funding announcement
  2. BioPharma Dive: Slate launch and financing
  3. Slate Medicines: company and announcement date
03 / Related rounds

Related funding rounds

01
Series A · Fusion Energy

Inertia Enterprises

Inertia Enterprises is developing laser-based fusion power, combining high-power lasers, manufactured fuel targets and a planned pilot plant.

Led by Bessemer Venture Partners
$450M
02
Undisclosed · Energy

SHINE Technologies

SHINE Technologies uses nuclear fusion technology for neutron testing, medical isotope production and the development of nuclear fuel recycling.

Led by NantWorks
$240M
03
Series A · AI

Fundamental

Fundamental develops NEXUS, a foundation model for making predictions from structured business data in tables.

Led by Oak HC FT
$225M